Haloperidol Galvany Pharma

Haloperidol Galvany Pharma is a prescription intramuscular injection containing the antipsychotic active ingredient haloperidol. It is supplied in a standard injectable concentration (strength not specified) and is marketed in the European Union. Haloperidol belongs to the butyrophenone class and acts as a dopamine D2 receptor antagonist, used under medical supervision for certain psychiatric conditions. The formulation is intended for intramuscular administration by healthcare professionals and is regulated as a medication.

Haloperidol Galvany Pharma injection is indicated for the management of several acute psychiatric conditions.

- Schizophrenia, particularly when rapid control of symptoms is required. - Acute psychotic episodes, including those associated with substance use or medical illness. - Manic episodes of bipolar disorder presenting with severe agitation. - Severe agitation or hostility that poses a risk to the patient or others. - Adjunctive treatment during emergency stabilization of patients with known psychotic disorders. - Pre‑operative sedation in patients with psychotic symptoms requiring surgical procedures.

Side effects of haloperidol injection can vary in frequency and severity; they are categorized as common or serious.

Common: - Drowsiness or sedation, often most noticeable after the first injection. - Mild extrapyramidal symptoms such as tremor, rigidity, or muscle stiffness. - Dry mouth and reduced salivation, leading to a sensation of thirst. - Constipation or slowed gastrointestinal motility.

Serious: - Neuroleptic malignant syndrome, a rare but life‑threatening reaction with fever and muscle rigidity. - Tardive dyskinesia, potentially irreversible involuntary movements after prolonged exposure. - Cardiac arrhythmias, including QT‑interval prolongation that may increase risk of torsades de pointes.

When prescribing haloperidol injection, clinicians should consider several precautions to minimize risks and ensure appropriate use.

- Assess cardiovascular status, as haloperidol may cause hypotension or QT prolongation. - Evaluate for a history of movement disorders, including Parkinson’s disease or prior extrapyramidal reactions. - Use the lowest effective dose for the shortest duration needed to control symptoms. - Monitor for signs of neuroleptic malignant syndrome, especially during the first few days of therapy. - Caution in patients with hepatic or renal impairment, adjusting dose as clinically indicated. - Avoid use in individuals with known hypersensitivity to haloperidol or other butyrophenones.

Haloperidol can interact with other medications; some combinations should be avoided while others require careful monitoring.

Avoid: - Concurrent use with other dopamine antagonists or high‑potency antipsychotics, which may increase extrapyramidal risk. - Co‑administration with drugs that markedly prolong the QT interval, such as certain antiarrhythmics or macrolide antibiotics.

Use with caution: - CNS depressants (e.g., benzodiazepines, opioids) may enhance sedation and respiratory depression. - Anticholinergic agents can mask early signs of extrapyramidal symptoms. - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin) may raise haloperidol plasma levels. - CYP3A4 inducers (e.g., carbamazepine, rifampin) may reduce therapeutic effectiveness.